Background: Hepatoblastoma is an embryonal liver tumor supposed to arise from the impairment of hepatocyte differentiation during embryogenesis. CTNNB1 is the only recurrently mutated gene, and this relative paucity of somatic mutations poses a challenge to risk stratification and development of targeted therapies. Methods: In this study, we investigated by exome sequencing the burden of somatic mutations in a cohort of 10 hepatoblastomas, including a congenital case. Results: Our data disclosed a low mutational background with only three recurrently mutated genes: CTNNB1 and two novel candidates, CX3CL1 and CEP164. The major finding was a recurrent mutation (A235G) identified in two hepatoblastomas at the CX3CL1 gene; evaluation of RNA and protein expression revealed up-regulation of CX3CL1 in tumors. The analysis was replicated in two independents cohorts, substantiating that an activation of the CX3CL1/CX3CR1 pathway occurs in hepatoblastomas, with a predominance of these proteins in the cytoplasm of tumor cells. These proteins were not detected in the infiltrated lymphocytes of inflammatory regions of the tumors, in which they should be expressed in normal conditions, whereas necrotic regions exhibited negative tumor cells, but strongly positive infiltrated lymphocytes. Our data suggested that CX3CL1/CX3CR1 upregulation may be a common feature of hepatoblastomas, potentially related to chemotherapy response and progression. In addition, three mutational signatures were identified in hepatoblastomas, two of them with predominance of either the COSMIC signatures 1 and 6, found in all cancer types, or the COSMIC signature 29, related only with tobacco chewing habit; a third novel mutational signature presented an unspecific pattern with an increase of C>A mutations. Conclusions: Overall, we present here evidence that CX3CL1/CX3CR1 chemokine signaling pathway is likely involved with hepatoblastoma tumorigenesis or progression, besides reporting a novel mutational signature specific to a hepatoblastoma subset.
INTRODUCTION
Hepatoblastoma (HB) is the most common malignant liver tumor in the pediatric population [1] , supposedly derived from hepatocyte precursors [2] . Although rare, there is a trend towards an increasing prevalence of HBs over the last years [3] . The cause of this rising in incidence is still unknown, but a possible explanation would be the increasing survival of premature children with low-birth weight, a factor associated with increased risk of HB [4] . In Brazil, collected data are concordant with the HB world prevalence (www.inca.gov.br/wcm/incidencia/2017). The overall 5-year survival rate of children with hepatoblastoma is 70% [5 , 6] ; however, patients who do not respond to standard treatment have very low survival rate [ [7] , [8] , [9] , [10] ]. Few cases in adults have also been described [ [11] , [12] , [13] ], and prognosis is most unfavorable. The Children's Hepatic Tumors International Collaboration (CHIC) has developed a novel risk stratification system on the basis of prognostic features present at diagnosis [14, 15] . Five backbone groups were defined according to clinical prognostic factors -age, AFP level (≤100 ng/mL), PRETEXT group (I, II, III, or IV), and metastasis at diagnosis.
HB genomes are relatively stable, with few cytogenetic alterations, mostly gains of chromosomes 2, 8 or 20 [[16] , [17] , [18] ]. The major driver mutations in HB tumorigenesis are mainly activators of the WNT pathway, with recurrent mutations in CTNNB1 [ [19] , [20] , [21] , [22] ]. Few other molecular mechanisms engaged in HB tumorigenesis include overexpression of IGF2 [23] and its transcriptional activator PLAG1 [24] , and down-regulation of RASSF1A by promoter hypermethylation [25] . This relative paucity of molecular biomarkers in HBs poses a challenge to proper stratification and adjustment of the therapeutic regimen, and molecular sub classification including gene signatures that could be used to stratify patients with hepatoblastoma were reported in the last years [ [2] , [19] , [26] ].
Exome sequencing has broadened the understanding of the HB mutational profile [ [19] , [27] , [28] , [29] , [30] ]. The commonalities disclosed by these studies, besides CTNNB1 mutations, were the low number of detectable somatic mutations, and pathogenic variants in genes from the WNT pathway, such as CAPRIN2 [27] . Other mutations were involved with the ubiquitin ligase complex (SPOP, KLHL22, TRPC4AP, and RNF169) [27] , and with the transcription factor NFE2L2, impairing the activity of the KEAP1/CUL3 complex for proteasomal degradation [19, 28] . Clinically, overexpression of NQO1, a target gene of NFE2L2, was significantly associated with poor outcome, metastasis, vascular invasion, and the adverse prognostic C2 gene signature [26] . Other two exome analysis were based on syndromic patients who developed HB, including a boy with Simpson-Golabi-Behmel syndrome carrier of a germline GPC3 loss of function (LoF) mutation (29) , and a girl presenting severe macrocephaly, facial dysmorphisms and developmental delay, in which a novel de novo germline nonsense mutation was detected in the WTX [30] . In a recent study [31] , 16 HBs were included in a pan-cancer cohort of pediatric tumors, with the identification of CTNNB1 and TERT, genes already known to be frequently mutated in this type of tumor.
We describe here the mutational signatures and exome findings of a cohort of ten HBs, disclosing somatic mutations relevant as well as revealing a potential new biological mechanism, corroborated by expression and protein analyses. In addition, germline mutations were investigated in a rare patient with congenital HB.
PATIENTS AND METHODS

Patients
This study was approved by Research Ethics Committee -A.C. Camargo Cancer Center, (number 1987/14). Participants and / or persons responsible signed an informed consent form. All methods were performed in accordance with the relevant guidelines and regulations. Fresh-frozen tumor and matched non-tumoral liver tissues and blood samples were retrieved from ten hepatoblastoma patients of the A. C. Camargo Cancer Center Biobank (ten HB samples=exome cohort, five matched non-tumoral liver tissues, and five matched blood samples). A validation cohort was used for targeted sequencing, and RNA expression studies, comprising 12 additional HB cases (11 from GRAACC -Adolescent and Child with Cancer Support Group -, and one from A. C. Camargo Cancer Center; clinical features of this second HB cohort are described in Supplementary Table 1 ). All patients received pre-surgery chemotherapy according to both SIOPEL (http://www.siopel.org/) and COG (https://www.childrensoncologygroup.org/) protocols. This work was approved by the A. C. Camargo Cancer Center and GRAACC ethics committee; samples were collected after signed informed consent obtained from parents. Patients were followed by clinical examination, imaging tests and alpha-fetoprotein dosage.
In addition to the Brazilian HBs cohorts, a validation set of 16 additional HBs was tested ( Supplementary Table 1 ; TCH samples). All these samples were de-identified specimens selected from the Texas Children's Hospital Department of Pathology archives (Molecular Oncology Laboratory), after IRB approval (Baylor College of Medicine Institutional Review Board).
DNA and RNA isolation DNA and RNA were extracted from liver and blood samples following the technical and ethical procedures of the A.C. Camargo Tumor Bank [32, 33] , using QIASymphony DNA Mini kit (QIAGEN) and RNeasy Mini Kit (QIAGEN). From tissue embedded in paraffin, direct cut (10 µg) and phenol-chloroform extraction were applied. Purity and integrity of DNA samples were checked by electrophoresis in 0.8% agarose gels and spectrophotometry (NanoDrop, Thermo Scientific), and RNA samples were evaluated by microfluidics-based electrophoresis (Bioanalyzer, Agilent Technologies); only high-quality RNA samples (RIN >7.0) were used for gene expression analysis.
Exome sequencing analysis
Exome data were obtained from genomic libraries of ten HBs and matched non-tumoral samples, enriched using the Sureselect 244K V3 (Agilent Technologies; n=11), OneSeq Constitutional Research Panel (Agilent Technologies; n=5), and QXT SureselectV6 (Agilent Technologies; n=4). Enriched libraries were sequenced on the Illumina HiSeq2500 platform using a 150-bp paired-end protocol to produce a median coverage depth on target of at least 50X per sample. Reads were mapped to their location in the human genome hg19/Grch37 build using the Burrows-Wheeler Aligner (BWA) package version 0.7.17. Local realignment of the mapped reads around potential insertion/deletion (indel) sites was carried out with the Genome Analysis Tool Kit (GATK) version 3.8. Duplicated reads were marked using Picard version 2.18, reducing false-positive SNP calls. Additional BAM file manipulations were performed with Samtools 1.7.
Base quality (Phred scale) scores were recalibrated using GATK's covariance recalibration. Somatic SNPs and indel variants were called using the GATK Mutect2 for each sample. A total of 53.43 Gigabases of sequence data were aligned at high quality (95% of aligned reads), with a mean of 4.45 Gb per sample. More than 95% of the sequenced bases presented Phred score >20. An average coverage depth of 42.6-fold per sample was achieved, with a median of 78% of target regions covered at a minimum of 20× read depth.
Data annotation and filtering variants were run through VarSeq software version 1.5.0 (Golden Helix) using the vcf. files. Variant annotation was performed using different public databases, including population frequency, such as EXAC (http://exac.broadinstitute.org/), gnomAD (Genome Aggregation Database -http://gnomad.broadinstitute.org/), ABRaOM (http://abraom.ib.usp.br/), 1000 genomes (http://www.1000genomes.org/), and dbSNP version 138 (http://www.ncbi.nlm.nih.gov/projects/SNP/); cancer mutation databases -COSMIC version 67 (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) and ICGC (http://icgc.org/) -, and clinical sources -Clinvar (https://www.ncbi.nlm.nih.gov/clinvar) and OMIM (https://www.omim.org). Variant filtering was based on quality (Phred score >17), read depth (>10 reads), variant allele frequency (>10%), population frequency (<0.001%), and predicted protein effect (missense, and LoF -essential splice site, frameshift and nonsense variants). In silico prediction of pathogenicity of missense variants were based on six algorithms provided by the database dbNSFP . The potential damaging effect was also assessed using the VEP32script software package from Ensembl (https://www.ensembl.org/). Likely pathogenic variants were visually validated as somatic alterations using both Integrated Genomics Viewer (IGV) and Genome Browser (Golden Helix).
Selected variants were validated by target sequencing; the gene panel was elaborated based on genes disclosed in the current exome analysis (Agilent's SureDesign platform with a total of 18,539 probes and a total size of 498,019 kbp). Libraries were prepared from 22 freshfrozen samples (exome and validation cohorts) using the 244K Agilent SureSelect Target Enrichment (Agilent Technologies) system; the TruSeq v2 chemistry 500 cycles kit was used with 250pb paired-end-protocol on the Illumina MySeq. The software SureCall (Agilent Technologies) was used for analysis.
Sanger Sequencing
Prioritized variants from five candidate genes (from our study and the literature; CTNNB1, CAPRIN2, CX3CL1, AXIN1, and DEPDC5) were validated by Sanger sequencing (sequences upon request) in the HB exome cohort of ten tumors, and investigated in 24 additional samples (12 HBs of the validation group; and additional 12 HBs from formalinfixed paraffin-embedded samples that were contained in a tissue microarray previously made in the Institution; the clinical information about the cases included in the tissue microarray is available in Supplementary Table 2 ). 14 HB cases from the Texas Children`s Hospital were screened for the CX3CL1 variant. PCR reactions were performed using standard conditions (95 °C, 5 min; (44 °C, 30 s.; * °C, 30 s.; 72 °C, 45 s) × 30 cycle; 72 °C, 10 min), and amplicons were sequenced in both directions using an ABI 3730 DNA sequencer (Applied Biosystems); sequences were aligned with the respective gene reference sequence using Chromas Lite software (Technelysium).
Gene expression analysis by real-time PCR
Gene expression was performed using the exome (n=9) and validation cohorts (n=10), and six liver tumor cell lines (HEPG2, C3A, SNU-387, SNU-423, SNU-449 and SNU -475) for CX3CL1 and CX3R1. RNA to cDNA conversion was made using the Applied Biosystems High Capacity RNA to cDNA kit following the manufacturer's protocol. For qPCR, we used TaqMan Universal Master Mix II (Applied Biosystems) with reactions performed on an ABI PRISM 7500 instrument. 18S was selected as the most stable reference gene among 18S, B2M, GAPDH and ACTA1 genes tested according to geNorm [34] . Averages from sample triplicates were compared between groups, considering differentially expressed those genes with fold changes ≥|2| through the 2 -ΔΔCt relative quantitative (RQ) method [35] , with p-value ≤0.05. Mann-Whitney test was applied in the analysis of all tumors and cell lines compared to the control group; paired tumor/normal tissue samples were compared using the Wilcoxon test. All tests were corrected using Bonferroni. Prism 6 software (GraphPad; CA, USA) was used for statistical analyses.
Immunohistochemistry
Protein analysis was performed for two genes (CX3CL1, and CX3CR1) using the following antibodies: Polyclonal Antibody PA5-23062 (CX3CL1), and Polyclonal Antibody PA5-19910 (CX3CR1), both from ThermoFisher scientific company. Reactions were automated in the BenchMark Ultra-VENTANA equipment or manual protocol (Novocastra Novolink kit). In total, immunohistochemistry were evaluated in 34 cases: nine HB samples from the exome cohort, 17 additional HBs from the tissue microarray [36] and eight samples from the Texas Children`s Hospital cohort, including a lung metastasis sample.
Mutational signature detection
Exome data of HBs and matched non-tumoral tissues were used to detect specific mutational signatures. All somatic single base substitutions were mapped onto trinucleotide sequences by including the 5` and 3` neighboring base contexts to construct a 96 x G matrix of mutations count. Next, we used signeR [37] to estimate the number of mutational processes and their signatures. Cosine similarity score was used to compare the signatures with the Pan-Cancer catalog of 30 signatures in COSMIC database.
RESULTS
Clinical features of the cohort of the ten HBs that were studied by exome sequencing are described in Table 1 . The mean age at diagnosis was 24.5 months, excluding one patient who was diagnosed at 17 years (HB28). One of the patients was syndromic (born premature, underweight, developmental delay, facial dysmorphisms, and craniosynostosis; HB46), and two others presented kidney abnormalities, including the patient that developed a congenital tumor (HB33). Four cases were classified as high-risk according to CHIC criteria, and three of these patients presented pulmonary metastasis at diagnosis. After histopathological reexamination, one case was reclassified as presenting HB/Hepatocellular Carcinoma (HCC) features (HB30). Three patients died from the disease, including the patient diagnosed at 17 years old and the case reclassified as HB/HCC features; the third patient (HB15) died from complications of liver transplantation.
Identification of somatic coding non-synonymous mutations by exome sequencing
The strategy of analysis of the exome sequencing data was designed to identify somatic variants, excluding non-coding and coding synonymous variants. Only LoF and missense somatic mutations, the later predicted to be pathogenic by at least one in silico algorithm, were considered in this analysis. A total of 94 somatic non-synonymous mutations were disclosed (92 different variants), mapped to 87 different genes ( Supplementary Table 3 ); the detected mutations were validated either by targeted or Sanger sequencing. Two HBs did not present detectable somatic non-synonymous coding mutations (HB17 and HB28), and another one (the congenital case HB33) was found to harbor 40% of the identified somatic mutation in this cohort. The mean number of somatic non-synonymous mutations per sample was 9.4; however, excluding the atypical sample (HB33), the median number of somatic nonsynonymous variants was 6.2 per tumor.
Four of these detected mutations were already reported in COSMIC, three of them in CTNNB1 (c.101G> A: COSM5671; c.101G> T: COSM5670; c.121A> G: COSM5664), and one in GMPS (c.1367G>T: COSM1040323). The same missense mutation (c.704C>G, A235G) was disclosed in the CX3CL1 gene in two tumors (HB32 and HB33). CEP164 gene was mutated in two tumors, although presenting different variants. Table 2 presents details of the mutations considered to be likely pathogenic: six LoF variants (five nonsense and one frameshift, five of them in a single tumor), and six missense variants (recurrent variants or recurrent genes in different tumors). A validation cohort of 12 HBs was screened for the full set of somatic variants, and only CTNNB1 mutations were detected.
Additionally, an integrative analysis based on previous DNA methylation (DNAm) data from the same group of HB samples [38] showed a partial overlap between the set of genes presenting somatic mutations and the set with DNAm changes: EGFR and LMBRD1, hypermethylated, and AHRR, hypomethylated, respectively.
To explore the pathways in which the mutated genes are involved and their biological roles, we used KEGG (Kyoto Encyclopedia of Genes and Genomes http://www.genome.jp/kegg; Release 86.1, May 10, 2018) and Gene Ontology (http://www.geneontology.org/; PANTHER Over representation Test, Homo sapiens -REFLIST 21042) databases. It was detected an enrichment for several development processes, Pathways in cancer, Proteoglycans in cancer, Metabolic pathways, Cytokine-cytokine receptor interaction, among others.
Known and novel CTNNB1 mutations
We investigated the presence of CTNNB1 mutations either by exome or Sanger sequencing in the ten HBs and additional 12 tumors from the validation group. A total of seven pathogenic variants were detected in eight samples. Six CTNNB1 missense mutations (G34E, G34V, T41A, D32A, S29F, and S33C; Figure 1a-e) , which had already been reported in HBs (COSMIC), and a novel likely pathogenic variant, a 39 bp inframe deletion (A21_S33del) (Figure 1f -HB40T ). All identified variants map in the CTNNB1 exon 3 (Figure 1e) , at GSK3β phosphorylation sites. Additionally, six tumors presented size-variable CTNNB1 intragenic deletions that were ascertained by Sanger sequencing. In summary, CTNNB1 alterations were detected in 14 out of the 22 tested HBs (64%).
Recurrent A235G somatic mutation in CX3CL1: a new HB gene?
The missense mutation C>G at the position 704 of the exon 3 of CX3CL1 (NM_002996) was identified in two samples (HB32 and HB33). This mutation leads to substitution of the amino acid alanine by glycine in the codon 235 of the protein, predicted as damaging for protein function by SIFT and Mutation Taster algorithms (Figure 2a) . The CX3CL1 variant was validated by target sequencing in both mutated tumors (Figure 2b) ; Sanger sequencing detected the mutation only in the tumor sample with the higher variant frequency (HB33, 40%). Another 47 HB samples were also tested for the presence of the A235G variant, but no mutations were identified.
CX3CL1 expression level was evaluated in 19 HB samples (including the two mutated ones), nine non-tumoral liver samples, two hepatoblastoma cell lines, and four hepatocellular carcinoma cell lines. Up-regulation of CX3CL1 was detected in the HB group, including CX3CL1-mutated tumors and HB cell lines, compared to control liver samples (fold-change >2; p<0.05) (Figure 2c) . The hepatocellular carcinoma cell lines were found to be down-regulated in relation to control samples and HBs. To investigate if the presence of the CX3CL1 mutation and/or up-regulation of its mRNA could influence the involved pathway, the expression of the CX3CL1 receptor (CX3CR1) was also assessed. Six tumors presented upregulation of CX3CR1 mRNA in relation to control (fold-change > 2), including one of the CX3CL1-mutated tumors (HB32; Supplementary Figure 1) . Vascular invasion was the only clinical characteristic with a trend towards CX3CL1 upregulation (64% of high-expression samples versus 25% of lowexpression; p<0.06, Chi-square test; data not shown). Expression of CX3CR1 and CX3CL1 did not seem to be correlated.
DNA methylation (DNAm) data at gene bodies and promoters of CX3CL1 and CX3CR1 were recovered for HB samples [38] to correlate with the expression level of these genes (Supplementary Figure 2) . A significant DNAm decrease was observed in CX3CL1 promoter in tumors compared to control liver samples (p-adj 0.006), and an inverse correlation between gene expression and DNAm level in the CX3CL1 gene body (Spearman's rho 0.46, P-value 0.02), although the latter presented great inter-tumor heterogeneity.
Protein analysis showed positivity of CX3CL1 in most of the investigated samples (20 out 26 HBs), presenting nuclear or cytoplasmatic labeling at different degrees (details available in Supplementary Table 4 ). HB32-mutated tumor exhibited weak cytoplasmatic labeling and nuclear positivity in more than 50% of cells, while HB33-mutated showed strong cytoplasmatic labeling and nuclear positivity in 25% of cells (Figure 3a1-c1) ; in particular, HB33 exhibited great heterogeneity of histology and protein labelling. Positive labeling of CX3CR1 was detected only in the two CX3CL1-mutated tumors (Figure 3a-c) ; HB33 showed cytoplasmatic signal, and HB32 had both nuclear and cytoplasmatic labeling. Non-tumoral liver samples did not show any labeling.
An independent set of eight HBs and one HB lung metastasis was also evaluated by immunohistochemistry, in a qualitative analysis; similarly to our previous observation, the pattern of protein expression indicated an activation of the CX3CL1/CX3CR1 pathway, with a predominance of these proteins in the cytoplasm of tumor cells ( Supplementary Table 5 ). It was observed that in inflammatory regions of the tumors, both proteins were not expressed in the infiltrated lymphocytes, in which they should be expressed in normal conditions, whereas in necrotic regions, the protein staining was negative in tumor cells, but strongly positive in the infiltrated lymphocytes. Figure 4 illustrates these findings.
Mutational signatures of HB
Three signatures were detected (HB-S1, S2, and S3), two of them (HB-S1 and HB-S2) presenting great superposition to mutational signatures already reported in COSMIC. The profile of each signature is displayed in Figure 5 using the six substitution subtypes (C>A, C>G, C>T, T>A, T>C, and T>G). HB-S1 group was most similar to COSMIC signatures 1 and 6, and HB-S2 group presented features of the COSMIC signature 29. HB-S3 showed no clear similarity to any known signature, presenting an unspecific pattern with a slight increase of C>A mutations. The relative signature contribution to mutations in each hepatoblastoma sample can be found in Supplementary Figure 3 .
Congenital HB case
Germline exome analysis was performed for this patient and her mother; father was unavailable. A total of 144 rare germline non-synonymous variants were identified in the patient, and absent from her mother (information on frequency and pathogenicity scores of the detected variants are available in Supplementary Table 6 ). Twelve germline variants were LoF (AARSD1, ACSM3, ERI2, CECR2, CRYGA, DNAH7, ETV4, HOXC4, MAMDC4, NEBL,  PRSS56, and TBXAS1) , standing out a stop gain in HOXC4, which was not previously reported in any germline database, including a cohort of Brazilians (ABRAOM), and an indel in the PRSS56 gene (ClinVar 31077), both variants already reported in liver cancer samples (ICGC). Additionally, the patient carries six missense variants which were predicted to be deleterious for protein function using six different algorithms; among them, a variant affecting BRCA1, and two others not documented in any database (GOLGA5 and FAH gene, Supplementary Figure 4 ).
DISCUSSION
Our exome findings revealed a low mutational background in HBs, corroborating previous works [ [19] , [26] , [31] ], with only three genes presenting recurrent mutations, namely CTNNB1, CX3CL1, and CEP164. CTNNB1 somatic mutations were detected in ~60% of the tumors here studied, including a novel pathogenic variant (A21_S33del). Mutation in the A2ML1 gene also appeared in common between our HB cohort and one of the major exome studies of HB samples [28] , although the role of A2ML1 somatic mutations remains unclear. Mutations in the promoter of the TERT gene was also reported as recurrently mutated in HBs; however, TERT promoter was not covered in this exome data.
Our data pointed out to a novel set of candidate genes for HB tumorigenesis. CEP164, a key element in the DNA damage-activated signaling cascade [39] involved in genome stability, was found to be mutated in two different HBs. CEP164 is overexpressed in various cancer types, often associated with poor prognosis [40] , and a recent study in rhabdomyosarcoma cells suggested a central role of this gene in proliferation in response to cellular stress [41] . Remarkably, one of the CEP164-mutated HBs exhibited a complex genome, with several copy number alterations and two large LOH regions. Three genes, which we have previously reported as differentially methylated in HBs [38] , were mutated in the present cohort, reinforcing a possible role in HB tumorigenesis: EGFR, LMBRD1, and AHRR. LMBRD1 encodes a lysosomal membrane protein and is associated with a vitamin B12 metabolism disorder [42] , and AHRR and EGFR are involved in regulation of cell growth and differentiation. Six LoF variants were identified in ACACA, ARVCF, DEPDC5, MYH7, NOL6 and KIAA0319L.Nevertheless, all but the ACACA variant were detected in the congenital tumor, making difficult to associate these mutations with HB in general.
The most significant finding in this study was the detection of a recurrent somatic missense mutation at the CX3CL1 gene. This gene, chemokine ligand 1 (C-X3-C motif), encodes a large transmembrane 373aa multiple-domain protein from the chemokine family, the fractalkine. This protein is present in endothelial cells of diverse tissues, such as brain, kidneys, and liver [43] , and is related to leukocytes movement, including migration to inflammation sites [44, 45] . The cell adhesion and migration functions are promoted through interaction of fractalkine with the chemokine receptor CX3CR1, a transmembrane protein known to provide pro-survival signaling for anti-inflammatory monocytes, but also present in NK cells and T cells [46] . The mutation is located in a region that exerts a key role related to the binding to CX3CR1. Under inflammatory response conditions, cleavage of CX3CL1 by metalloproteinases generates a soluble chemokine, which binds to CX3CR1 in nearby cells and can induce adhesion, cell survival, and migration. The significance of CX3CL1 mutations in cancer is yet poorly understood, but mutations in different types of tumor are reported, predominantly in gastric cancer (COSMIC) and hepatocellular carcinomas (TCGA). Gastric tumors exhibit increased CX3CL1 expression [47] , and the CX3CR1 receptor is highly expressed in association with more advanced stages. Xu et al. [48] and Yang et al. [49] published results of another chemokine (CXCL5) in liver cancer, with data also indicating an oncogenic role.
Expression studies showed CX3CL1 upregulation in hepatoblastomas, a result that was corroborated by immunohistochemistry assays. We also observed increased CX3CL1expression in several HBs without detectable CX3CL1 mutations, suggesting alternative pathways for its activation, such as the significant hypomethylation at the CX3CL1 promoter disclosed in HBs. CX3CR1 expression was increased in only part of the tumors, but it was noteworthy that only the two CX3CL1-mutated tumors presented CX3CR1 protein, evidencing an activation of this chemokine pathway. Our results indicate that the activation of the CX3CL1-CX3CR1 pathway could be related to HB progression. Inappropriate expression or regulation of chemokines and their receptors are linked to many diseases, especially those characterized by an excessive cellular infiltrate, such as rheumatoid arthritis and other inflammatory disorders. In recent years, the involvement of chemokines and their receptors in cancer, particularly metastases, has been well-established [50, 51] . Chemokines produced serve to recruit leukocytes, which produce other cytokines, growth factors, and metalloproteinases that increase proliferation and angiogenesis. The metastasis process is facilitated by the regulation of particular chemokine receptors in tumor cells, which allows them to migrate to secondary tissues where the ligands are expressed [52] . In an independent HB group, a contrasting pattern of CX3CL1 and CX3CR1 was observed in regions of inflammation in the samples, and in areas with necrosis. Around necrotic regions, CX3CL1 and CX3CR1 were detected in the infiltrated lymphocytes, indicating a normal immune response; however, in inflammation regions both proteins were strongly positive in tumor cells and not detected in infiltrated lymphocytes, suggesting a mechanism of regulation of this pathway in favor of HB cells. This result further adds to previous studies showing that the activation of the ligand and receptor in chemokines may be involved in tumor invasion [ [47] , [48] , [49] ]. All these pieces of evidences reinforce the importance of the study of chemokines in tumors in general, and in HBs in particular.
In addition to revealing coding somatic mutations in HBs, exome data was used to search for mutational processes. In general, it was remarkable that the mutational signatures already reported specifically for liver cancer were not observed in these HBs, suggesting distinct mutational mechanisms for hepatocellular carcinomas and liver embryonal tumors. Two of the three different mutational signature here observed have superposition mainly with three known signatures from COSMIC (signatures 1, 6 and 29). Signature 29 has been observed only in gingiva-buccal oral squamous cell carcinoma developed in individuals with a tobacco chewing habit; this signature indicates guanine damage that is most likely repaired by transcriptioncoupled nucleotide excision repair. Among the several chemicals in smokeless tobacco that have found to cause cancer [55] , the most harmful carcinogen are nitrosamines, which level is directly related to the risk of cancer and that can be also find in food such as cured meat, smoked fish and beer. Interestingly, O(6)-methylguanine detected in human cord blood in mothers highly exposed to such products implicates Nitrosodimethylamine exposure of the fetus and toxicity from dietary sources of these compounds [56] . Maternal dietary exposure to N-nitroso compounds or to their precursors during pregnancy has also been associated with preterm birth [57] and risk of childhood cancer [58] . Childhood cancer is most probably the combinatorial result of both genetic and environmental factors, and these networks between fetal exposure to environmental carcinogens such as nitrosamines from tobacco and/or dietary sources, preterm birth, and increased risk of childhood cancer may be an underlying cause for at least a subset of HBs. Finally, a subset of tumors, including two patients who died from the disease, exhibited a mutational pattern with no clear similarity to any known signature.
As a final point, we analyzed the germline exome of the patient with a congenital HB and renal agenesis, who developed a tumor exhibiting a heterogeneous histology. This tumor presented the highest number of somatic mutations herein detected, including CX3CL1 and CTNNB1 mutations, and its chromosome copy number profile was complex compared to the HB group (data not shown). In addition to very rare germline variants in genes related to liver function, such as HOXC4, PRSS56 and CYP1A1, the patient carried two variants strongly predicted to be deleterious affecting BRCA1 and FAH, both genes associated with cancer predisposition [59] . In particular, the FAH gene encodes a fumarylacetoacetate hydrolase enzyme that is mainly abundant in liver and kidneys [60] , and germline mutations were already reported to increase the risk of hepatocellular carcinoma [61] , although only in a recessive mode of inheritance.
Several lines of evidence indicate that childhood and adult cancers are distinct entities. In spite of intensive efforts, relevant genetic factors remain difficult to be captured in rare cancers such as embryonal tumors like HB. In summary, in this study, we provide new evidences that the activation of the CX3CL1/CX3CR1 chemokine signaling pathway can be involved in hepatoblastoma tumorigenesis or progression. We present the first assessment of mutation signatures in hepatoblastomas identifying a novel signature specific to a subset of these tumors. Additionally, we draw attention to the aspect of a likely strong genetic component of cancer predisposition at least in part of the HB patients, possibly related to the presence of additional clinical signs such as kidney abnormalities. 
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Fig 4: Protein expression of CX3CL1 and CX3CR1 evaluated in hepatoblastomas and hepatoblastoma lung metastasis by immunohistochemistry assay:
Panels a-d shows CX3CL1 data, and panels a1-d1, CX3CR1. A. TCH361, CX3CL1 strongly positivity of infiltrated lymphocytes (indicated by arrow 1) in necrotic regions of the tumor, and A1. CX3CR1 strongly positivity of infiltrated lymphocytes (indicated by arrow 2) in necrotic regions of the tumor; B. and B1. TCH327, positivity in tumor cells (indicated by arrows 3 and 5) and infiltrated lymphocytes negative (indicated by arrows 4 and 6) for both proteins. C. TCH321, positivity in the osteoblast component and strong positivity in the fetal type (indicated by arrow 7); infiltrated lymphocytes are negative (indicated by arrow 8); C1. Positivity in tumor cells and lymphocytes negative; D. and D1. TCH360, lung metastasis showing positivity in tumor cells (indicated by arrows 9 and 11), and no expression in infiltrated lymphocytes (indicated by arrows 10 e 12), for both proteins. (37) . The profile of each signature is displayed using the six substitution subtypes (C>A, C>G, C>T, T>A, T>C, and T>G).
